Search results: (10000)
News Maintenance Therapy After Oxaliplatin Discontinuation Based on Panitumumab
Panitumumab is an approved therapy for metastatic colorectal cancer without RAS oncogene mutation (wtRAS mCRC) and has been evaluated for 1st-line treatment through randomized phase II (PEAK) and III (PRIME) studies. A retrospective analysis of these studies assessed the efficacy and safety of panitumumab as the basis for therapy in these patients after discontinuation/termination of oxaliplatin.
News The Patient Will Feel Comfortable Only with a Properly Chosen Absorption Aid
While before the approval of the amendment to the Public Health Insurance Act, it was possible to issue a prescription only for one type of aid firmly tied to a particular level of incontinence, now it is allowed to freely combine aids according to the individual needs of the patient. The modern market offers a wide range of aids − but how to choose a product that matches specific needs?
News Clinical Profile and Outcomes of Patients with Cardiac Amyloidosis – Spanish Experience from Real Practice
Cardiac amyloidosis is caused by the deposition of amyloid fibrils in the myocardium and is among the diseases with significant diagnostic delay. Physicians from the University Hospital in Madrid shared their experiences with the diagnosis and treatment of these patients over the last decade in the cited work below.
News Direct Oral Anticoagulants and Their Reversal Agents – Current Options
In the last 10 years, the options for anticoagulant therapy have expanded with the introduction of direct oral anticoagulants (DOACs). It appears that DOACs may soon replace warfarin in the first line of prevention of venous thromboembolism, not only due to their clinical advantages but also thanks to newly available reversal agents that can be administered in case of major bleeding in patients taking DOACs. A recently published review article summarizes the current situation in this area.
News Long-term Benefit of Sotorasib for Survival of Patients with Pre-treated Advanced/Metastatic NSCLC with G12C Mutation of KRAS Oncogene
Sotorasib is indicated as monotherapy for advanced non-small-cell lung cancer (NSCLC) with the KRASG12C gene mutation, if there has been progression after ≥ 1 prior line of systemic therapy. The 2-year analysis of data from the CodeBreaK 100 study published in April 2023 demonstrated the long-term benefit of sotorasib for this patient population in terms of progression-free survival (PFS) and overall survival (OS), regardless of programmed death-ligand 1 (PD-L1) receptor expression, including patients with a poor prognosis. In the Czech Republic, sotorasib has been reimbursed by public health insurance for this indication since September 2023.
News Frequent Nausea During Chemotherapy Despite Antiemetic Prophylaxis
Current clinical research has focused on vomiting as a primary issue in the occurrence of CINV (chemotherapy-induced nausea and vomiting) and, using recommended antiemetic prophylaxis, this problem has been relatively well managed. However, the incidence and impact of nausea are underreported. We present the results of an observational study that evaluated the incidence of nausea in patients undergoing chemotherapy.
News Meta-analysis of Efficacy and Safety of Third-Generation Antiseizure Medications in Adjunctive Treatment of Focal Seizures in Adults with Epilepsy
Epilepsy treatment is primarily symptomatic, aimed at reducing seizure frequency. However, more than 50% of patients do not achieve seizure freedom with monotherapy. Below we summarize the results of a meta-analysis comparing the efficacy and safety of third-generation antiseizure medications in the treatment of focal seizures in adults with epilepsy.
News Monitoring Limits in Prescribing Incontinence Aids is Essential
The amendment to the Public Health Insurance Act, which came into effect in December 2019, brought many changes in the reimbursement of medical aids through prescriptions. The methodology for determining the degree of incontinence has changed, and it is now also possible to combine aids according to the individual needs of the patient. We summarize other novelties related to limits issues in the following text.
News Pharmacokinetics of Concentrates for the Treatment of von Willebrand’s Disease
Von Willebrand's disease (vWD) is characterized by a deficiency or reduced functional capacity of von Willebrand factor (vWF) and, in more severe cases, by a deficiency of coagulation factor VIII (FVIII). Treatment usually requires repeated infusions of vWF and FVIII concentrate, with available products having different factor ratios. Repeated infusions of concentrates can lead to different FVIII exposures when using different products. The pharmacokinetics of two products with varying vWF and FVIII ratios have been compared in experimental preclinical and clinical studies.
News Options for Modifying and Improving the Efficiency of the HJHS Scoring System
The Hemophilia Joint Health Score (HJHS) is a validated tool for assessing joint health in individuals with hemophilia. Can it be modified to be used more effectively in clinical practice?
News Anticonvulsants Are Associated with the Least Impact on Sexual Function in Bipolar Disorder Treatment
It is known that in patients with bipolar disorder, in addition to the illness itself, sexual dysfunction is adversely affected by psychotropic medications. A study by Spanish authors recently published in the Journal of Sexual Medicine compared the treatment of different groups of mood stabilizers in patients with bipolar disorder in terms of adverse effects on sexual function.
News Low-Molecular-Weight Heparin as Adjuvant Therapy in Small-Cell Lung Cancer − Results of the RASTEN Study
Several studies and meta-analyses in the past have pointed to a possible positive effect of low-molecular-weight heparins (LMWH) in the treatment of cancer. The RASTEN study therefore focused on the potential effect of enoxaparin in patients with small-cell lung cancer (SCLC).
News The Choice of Incontinence Aids Matters − But How Not to Get Lost Among Them?
Despite significant advances in medicine, a large number of patients still struggle with incontinence, which limits their comfort and reduces their quality of life. If treatment options have been exhausted, these patients rely on the use of incontinence aids, and therefore every urologist and general practitioner should be familiar with the current offerings and their applications.
News Safety of Dabigatran in Secondary Prevention of Venous Thromboembolism in Pediatric Patients
Low molecular weight heparin (LMWH) or warfarin (VKA – vitamin K antagonist) is typically used for the secondary prevention of venous thromboembolism. The DIVERSITY study extension examined the safety of dabigatran in this indication in pediatric patients.
News Does the type of oral anticoagulant affect heparin dosing during catheter ablation?
During catheter ablation, which patients undergo as part of atrial fibrillation (AF) treatment, current guidelines recommend the administration of heparin without interrupting oral anticoagulant therapy. A recently published analysis evaluated whether the type of oral anticoagulant affects the total dose of heparin administered during the ablation.
News Which Dietary Recommendations Actually Work for Irritable Bowel Syndrome?
Food is both a trigger for symptoms and a treatment tool for individuals with irritable bowel syndrome (IBS). A 2021 review summarizes the results of the latest research on the effectiveness of dietary measures for IBS and the evidence of which measures are truly beneficial. A positive impact was found for general healthy eating recommendations, soluble fiber supplementation, a low short-chain carbohydrate diet, and probiotic administration.
News Innovation in Wound Healing: Zetuvit Plus Silicone Border for Optimal Wound Exudate Management
Excessive wound exudate can lead to delayed healing, skin damage around the wound, or leakage under the chosen dressing. Zetuvit Plus Silicone Border dressing with high absorbent and retention capacity offers confidence in treating both chronic and acute wounds and high comfort for the patient.
News 6-year data from the ECHELON-1 study: How does combining brentuximab vedotin with chemotherapy affect overall survival of previously untreated cHL patients?
At this year's annual congress of the European Hematology Association (EHA), results from the analysis of 6-year data from the international randomized open-label phase III ECHELON-1 study on overall survival of patients with classical Hodgkin lymphoma (cHL) stage III/IV who received a combination of brentuximab vedotin with chemotherapy in the first-line treatment were presented, among other findings.
News Medium to Long-term Results of PFC Sigma Total Knee Arthroplasty
The PFC Sigma knee implant was introduced in 1997. It is the most commonly used system for total knee arthroplasty in England and Wales, accounting for 34.9% of primary implantations in 2006. Studies evaluating medium to long-term implantation outcomes have shown that it is an implant with a high survival rate, low re-implantation rate, and very good clinical results.
News Cenobamate in the Therapy of Pharmacoresistant Epilepsy in a Warfarinized Patient – A Case Study
A case study from Czech practice presents a patient with pharmacoresistant epilepsy and concurrent warfarin medication for heart valve replacement, where the INR value remained within the cardiologist’s recommended range without further adjustments to anticoagulant therapy during combined antiepileptic therapy with cenobamate (CNB) under the recommended dose titration.
News Pitfalls of Levothyroxine Replacement Therapy
Hypothyroidism (reduced function of the thyroid gland) affects approximately 1-2% of the population. Its prevalence increases with age and it is more common in women. Synthetic thyroid hormone levothyroxine is used to treat hypothyroidism. It is a widely prescribed medication available in tablets of various strengths.
News What did the first data from the pilot lung cancer screening show?
Czech pulmonologists have released the first interim results of this year's pilot testing of heavy smokers due to the risk of lung cancer. More than 4,000 patients passed through the hands of general practitioners, and 900 subsequently underwent low-dose CT examination. What other specific findings emerge from the data collection? And what challenges do the experts involved in this program face?